In this report, covers the present scenario (with the base year being 2017) and the growth prospects of global Benign Prostatic Hyperplasia (BPH) Drugs market for 2018–2023.
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body.
Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH.
Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual.
Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40–59 years; however, in the age group of 60–69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period.
Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.Over the next five years, projects that Benign Prostatic Hyperplasia (BPH) Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions.To calculate the market size,considers value and volume generated from the sales of the following segments:
Segmentation by product type:
- Phosphodiesterase Type-5 Inhibitors
- 5-Alpha-Reductase Inhibitors
- Segmentation by application:
This report also splits the market by region:
- United States
- Southeast Asia
- Middle East & Africa
- South Africa
- GCC Countries
Download free sample PDF of this report @ https://www.grandresearchstore.com/report-sample/global-benign-prostatic-hyperplasia-drugs-2018-2023-924
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
- Astellas Pharma
- Eli Lilly
- ADC Therapeutics
- Bayer HealthCare
- Bristol-Myers Squibb
- Valeant Pharmaceuticals
- Endo Pharmaceuticals
- Foresee Pharmaceuticals
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
To study and analyze the global Benign Prostatic Hyperplasia (BPH) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Benign Prostatic Hyperplasia (BPH) Drugs market by identifying its various subsegments.
Focuses on the key global Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Benign Prostatic Hyperplasia (BPH) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Benign Prostatic Hyperplasia (BPH) Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Table Of Content
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013–2023
2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
3 Global Benign Prostatic Hyperplasia (BPH) Drugs by Players
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players
3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Players (2016–2018)
3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players (2016–2018)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players
Key Que Answered in this report:
- What will the Benign Prostatic Hyperplasia (BPH) Drugs market the growth rate be in 2025?
- What are the key factors driving the Global Benign Prostatic Hyperplasia (BPH) Drugs market with a focus on the Chinese market?
- What are the key market trends in Benign Prostatic Hyperplasia (BPH) Drugs market?
- improve pacting the growth of the Global Benign Prostatic Hyperplasia (BPH) Drugs market?
- What are the challenges to Global Benign Prostatic Hyperplasia (BPH) Drugs market?
- What are the market opportunities and threats faced by the vendors in the Global Benign Prostatic Hyperplasia (BPH) Drugs market?
- What are the key outcomes of the five forces analysis of Benign Prostatic Hyperplasia (BPH) Drugs market?
What is our report offers:
Strategic suggestions and proposals for the beginners to understand
Assessments of the market share from different countries and regions were conducted
Top key market players, market share analysis included.
The market observations such as constraints, drivers, threats, opportunities, investment opportunities, challenges, and recommendations are added.
The competitive landscaping mappings of the ongoing trends are discussed.
Based on the market estimations, the strategic recommendations are made in the business segments
If You Have Any Question Related To This Report Contact Us @ https://www.grandresearchstore.com/enquire-now/global-benign-prostatic-hyperplasia-drugs-2018-2023-924
276 5th Avenue, New York , NY 10001, United States
Int’l: (+1) 646 781 7170 +91 8087042414
Follow Us On linkedin :- www.linkedin.com/company/grand-research-store